We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TRLS Trellus Health Plc

0.00 (0.00%)
23 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 1.50 1.80 1.65 1.65 1.65 50,310 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors 19k -6.34M -0.0392 -0.42 2.66M
Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 1.65p. Over the last year, Trellus Health shares have traded in a share price range of 1.65p to 9.20p.

Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £2.66 million. Trellus Health has a price to earnings ratio (PE ratio) of -0.42.

Trellus Health Share Discussion Threads

Showing 76 to 97 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
Cardiovascular disease company, focused on clinically-proven genomic precision testing products, to seek admission to AIM through an IPO

GENinCode plc, the cardiovascular disease ("CVD") risk assessment company focused on predictive genetics for the prevention of cardiovascular disease, is delighted to announce its intention to seek admission of its issued and to be issued Ordinary Shares to trading on AIM, a market of the London Stock Exchange plc ("Admission"). On admission, the Company is expected to have a market capitalisation of approximately £42 million.

The Company's product portfolio draws on genomic precision testing using polygenic (multiple-genes) technology, advanced molecular testing, genotyping and sequencing. Through a simple blood or saliva sample, the Company can analyse a patient's medical information and genetic variants associated with CVD to determine a Genetic Risk Score which is used for the subsequent assessment of a patient's cardiovascular disease risk. The Company also provides risk assessment for thrombosis (genetic predisposition to blood clotting). The Company's SITAB system, a proprietary software, bioinformatics and algorithmic platform with online cloud-based reporting, is used to process and record test results and genetic information using algorithms and artificial intelligence to assess a patient's risk of a cardiovascular event. SITAB reports results directly via a web portal to healthcare practitioners, cardiologists and physicians, in a user-friendly format.

The current standard of care for primary prevention and assessment of the risk of CVD has been in use and largely unchanged for many years. It is based on risk assessment equations which evaluate 'classic' or 'traditional' cardiovascular risk factors such as age, gender, smoking, blood cholesterol levels and blood pressure among other factors for the onset of CVD. The equations enable physicians to categorise patients as being at low, moderate or high risk of a CVD event, usually over the subsequent 10-year period or sometimes using a 'lifetime' horizon from which the patient is then assessed for lifestyle changes or treatment.

It is recognised that these 'classic' or 'traditional' risk assessments are imperfect with events not infrequently occurring in those individuals categorised at 'low' or 'intermediate' risk. The advent of genetic risk assessment for CVD is now able to help identify and reclassify those individuals traditionally categorised in the 'low' or 'intermediate' risk populations who are at higher genetic risk of a CVD event than their current standard of care risk assessment suggests. This enables earlier in life preventative measures to be adopted to lower the future risk of a CVD event.

With CVD mortality levels continuing to rise globally, there is an increasing need for cardiologists to apply genetics to help advance patient prognosis and diagnosis to treat the onset of CVD. The Company's products combine predictive models of genetics and patient data using classic cardiovascular risk factors (CVRFs) and are designed to improve predictive capability and genetic risk assessment to provide a personalised and thereby tailored treatment pathway. Recent studies and scientific reports show the correlation between genetic load/burden and the onset of CVD. The Directors believe that GENinCode's technology is at the forefront of genetic risk assessment in the CVD space.

The Company's key products are CE-Marked with the core products Cardio inCode and Thrombo inCode having IP protection in the major growth markets of Europe, the UK and the United States. The Company has now commenced its commercial expansion programme in Europe, the UK and the United States.

On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US.

The Company's commercialisation strategy in the US is a significant part of GENinCode's long-term growth and commercial strategy. The Directors expect Cardio inCode to be reviewed by the FDA as a De Novo device. The Company submitted an initial application to the FDA in February 2021 for Breakthrough Device designation for its Cardio inCode product. The FDA review is ongoing with a decision expected in Q3 2021.

Prior to Trellus listing, on the EKF thread I posted that there were large players interested and investing in the IBD space. The following is one example -

STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
Jul 09, 2021
United States
55.2 percent of patients were in symptomatic remission and 96.4 percent of patients were corticosteroid-free at week 152

New data from the UNIFI study is one of 22 Janssen abstracts, including five oral and three digital oral presentations, at the 16th Congress of the European Crohn's and Colitis Organisation

SPRING HOUSE, Pa., July 9, 2021 -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented today as a digital oral presentation (DOP83) at the 16th Congress of the European Crohn's and Colitis Organisation.1

"Despite recent substantial therapeutic gains, many patients living with ulcerative colitis still struggle to find lasting relief from their disease symptoms, especially without the use of steroids that can be associated with debilitating side effects when used long-term," said Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) at the Icahn Institute for Medicine at Mount Sinai.b "The LTE of the UNIFI study underscores the importance of studying therapies long-term, with results showing ustekinumab as both an effective and enduring treatment option for patients living with moderately to severely active ulcerative colitis."

Our Commitment to
Welcome to the Janssen Immunology Gastroenterology Newsroom! Below, please find the latest on our Gastroenterology news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for diseases such as Crohn’s disease (CD) and ulcerative colitis (UC).

Janssen’s Commitment to Gastroenterology
A Message from our Gastroenterology Disease Area Leaders

Dear All,

At Janssen Immunology, we remain steadfast in our commitment to address unmet need, uncover novel treatment approaches, and work collaboratively to deliver transformational therapies for patients with gastrointestinal (GI) diseases, including inflammatory bowel diseases (IBD) like CD and UC. We understand that significant unmet need remains in these conditions, and that many patients around the world are struggling to find the right treatment, maintain symptom relief and achieve remission. These patients are the motivating force that drives us to continue to pioneer research and achieve our vision to restore health for all patients with GI diseases.

Learn more about our research below!

It's one reason why I keep the Trellus Health Website strap line in mind - Precision Medicine Meets Resilience-Driven Care which I have added to the header post.

Telehealth: A quarter-trillion-dollar post-COVID-19 reality?
July 9, 2021 | Article

Strong continued uptake, favorable consumer perception, and tangible investment into this space are all contributing to the continued growth of telehealth in 2021. New analysis indicates telehealth use has increased 38X from the pre-COVID-19 baseline.

Update: July 9, 2021
Early in the COVID-19 pandemic, telehealth usage surged as consumers and providers sought ways to safely access and deliver healthcare. In April 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February 2020 (Exhibit 1).

Jul 13, 2021

Doctors And Human Resources Investing In Telehealth
Forbes Technology Council
Eran OrrForbes
Forbes Technology Council

When Covid-19 hit the United States, telehealth became front and center as a method to treat patients remotely, providing care to patients while keeping them and the doctors safe. According to a McKinsey & Company article, telehealth rose 46% in 2020 compared to 2019 when only 11% of U.S. patients used the remote service. The article also notes that since telehealth adoption rates of both patients and doctors are increasing rapidly and telehealth is becoming popular for more than just urgent care, there is $250 billion of health care revenue that could "potentially be virtualized."

According to CB Insights (via Fierce Healthcare), telehealth investment reached a peak at $4.2 billion in 139 deals for the first quarter of 2021, which is almost double of what it was last year, at the same time.

Health care is taking a new turn and finally catching up to the 21st century.

Companies understand that health and well-being (physical and mental health) affect employees’ job performance. To create ongoing support for their employees, companies worldwide are using telehealth solutions to treat patients for ongoing symptoms. An example of this is the recent announcement that Amazon has signed up multiple companies to their telehealth services, Amazon Care.

With the recent investments in telehealth, I expect that the industry will grow substantially. Patients enjoy being treated in their own homes and will not be so quick to return to in-office appointments, unless necessary. Covid-19 just kick-started an industry that was destined to grow and match the rise of technology.

What Covid-19 brought out of the woodwork is how technological advances can be used creatively to achieve the same result as what was once done in person. And sometimes people can achieve even better results when the work is done from afar.

Full story -

Two stories that particularly caught my attention -

Digital health funding in 2021 smashes last year's record with $14.7B
Published July 7, 2021

Dive Brief:
The first half of 2021 alone brought in $14.7 billion in digital health funding, quickly zooming past the previous annual record set last year, according to Rock Health.

The first half saw 372 deals with an average size of $39.6 million, spearheaded by 48 megadeals of $100 million or above that made up almost 60% of the half's total funding.

And that interest isn't limited to the private sector: Public exits also snowballed, with 11 completed IPOs and mergers with special purpose acquisition companies (an increasingly popular albeit nontraditional route to going public), compared to just seven exits in 2020. The consultancy expects another 11 SPACs to close in 2021.

Dive Insight:
The coronavirus catapulted digital health into the mainstream last year, resulting in a flurry of big deals, high-profile exits and historic levels of funding flowing in. That momentum has only accelerated in 2021, according to the report. Just halfway through the year, funding has already surpassed the annual record set in 2020, with the first half of 2021 comprising the two largest quarters of funding activity in the U.S. digital health market ever.

Monthly funding in June alone of $3.1 billion was almost triple that of June last year, which brought in $1.1 billion as funding first began to accelerate after initial coronavirus lockdowns.

"The digital health investment climate in one word: Up," researchers wrote in the report.
Full article -

This one was also notable -

Wellforce announces migration of the health system’s digital healthcare ecosystem to AWS
by Dr. Shafiq Rab, Chris Noonan, Shirley Golen, and Steve Malme | on 08 JUL 2021

Wellforce is migrating its entire digital healthcare ecosystem to create a digital platform on Amazon Web Services (AWS). This platform consists of the infrastructure for Epic, as well as a complex integration of more than 300 supporting healthcare and business applications. Today, 800 people within the system involved in the build, preparation, and coding of the system have access to the full ecosystem. Wellforce’s goal is to go live on two clinical systems this September and launch fully in spring 2022.

Once live, Wellforce is expected to be the largest organization to run the entirety of their Epic infrastructure on the cloud. Migrating away from an outdated, non-interoperable system of individual servers increases opportunities to scale and use artificial intelligence (AI) and other platforms to enhance the access and delivery of care. Having Wellforce’s entire ecosystem in the cloud also provides a redundant environment and increases access as well as opportunities for collaboration, research, and education.

“We are creating a frictionless and culturally competent care environment for patients, physicians, and the entire care team by migrating our entire digital healthcare ecosystem to the AWS Cloud. This enables our Wellforce team to integrate data-driven intelligence into everyday health and care that is more secure, resilient, and simple to use,” said Rab.

By taking the lead in digital healthcare transformation, Wellforce is estimated to save as much as 20 percent annually (approximately $3 million USD) through the modernization of the healthcare IT ecosystem using the cloud. This innovative approach serves as one of the first examples that healthcare systems across the nation, and world, can replicate.

Full story -

Biden admin 'absolutely supportive' of telehealth once crisis ebbs, Becerra says
Published July 1, 2021

Rebecca Pifer

Dive Brief:
The Biden administration's top health policy official reiterated his support for expanded telehealth access after the COVID-19 national emergency expires, as Congress considers a slate of bills that would permanently nix regulatory barriers to virtual care.
"We are absolutely supportive of efforts to give us the authority to utilize telehealth in greater ways," HHS Secretary Xavier Becerra said at a virtual event last week on digital health hosted by The Washington Post.

Becerra also stressed that, though affordable telehealth should be available to all, HHS would be doubling down in making sure there's accountability for quality of care. "We're going to be doing a lot of bird-dogging, a lot of oversight," he said.

Dive Insight:
Telehealth use skyrocketed in the early months of COVID-19 as Washington rolled back restrictions to digitally delivered care, allowing patients, kept out of doctor's offices by state restrictions and fears of virus transmission, to turn to virtual care in droves. As COVID-19 cases waned amid increased vaccination, so too have telehealth visits declined. Still, they remain significantly elevated compared to pre-COVID-19 levels.

Congress is currently deliberating what expanded virtual care flexibilities should remain after the COVID-19 national emergency. Bipartisan lawmakers have expressed support for nixing originating site and geographic requirements to coverage that made it difficult to use telemedicine widely and allowing traditional Medicare to reimburse broadly for the service.

The Alliance for Connected Care is currently tracking 43 bills that include significant telehealth or remote monitoring provisions introduced over the course of COVID-19.

Becerra, the first Latino to hold the role, reiterated Thursday that HHS supports pathways to broader telehealth use in Congress, but stressed it was important to ensure equitable access in doing so.

Full story -

Just in case you missed it yesterday.

Marvellous insights from Christopher Mills of Harwood Capital - a world class investor - talking about top quality stocks, such as Trellus health.

Heaven personified

I have received my share certificates too.
Share certificate received
From the HARGREAVE HALE AIM VCT PLC Half Year Report ending 31 March 2021 -

Page 21 - On 29 January 2021, the VCT received 184,615 Trellus Health Shares through an in-specie distribution from EKF Diagnostics plc. The shares were valued at nil at the balance sheet date.

The Company has made the following investments since the period end

Page 50 - Trellus Health plc (Amount Invested £000) - 1,000

ppmm...I am not too fazed by the delay (as I have no intention to sell), but it would be good to get the follow-up call that was indicated, so that I can put in motion what's required in order to lodge the certificates etc.

Btw, if you do phone Link, it seems best to chose the call-back option, which they have responded to on the two occasions that I have used it.

Wan, i’m in the same position and have not yet received my share certificate.
Trellus Health (9mins 50secs) was also talked about by capital markets expert Jamie Constable of N+1 Singer here yesterday.

Given the regulatory issues and compliance etc, the direct process was somewhat demanding but manageable in my view.

Barclays still managed to make life difficult though, and although they eventually supplied the evidence of my EKF holding, their first attempt was incorrect and not even relevant, and the second attempt was not complete as it did not include my SIPP EKF holding. Given the time constraints, I gave up and just sent what Barclays delivered on their second attempt.

Not that I have any intentions to dispose of shares any time soon. I also phoned Link earlier this week as I have not received the share certificates (which will be another bind to administer, including having to lodge the certificates with my broker etc). According to Links records they have already posted the certificates, but would still make further checks to confirm (not sure why they need to check if their records are correct), but I am still waiting for confirmation on this. They will look to re-issue new certificates if 'I think' that the certificates have been lost in the post! As I have not yet had further confirmation either way, I am still unsure as to what happens next.

I too am very impressed with EKF, and I think that EKF have delivered for investors with another excellent IPO and have been further considerate in also making shares available to retail investors by way of the restricted offer. Given the regulatory issues I am not sure whether the process itself could be any smoother, but clearly organisations such as Link and some brokers, could and indeed should have performed better, a lot better, and Barclays Smart Investor gets special mention in this regard!

Good morning James188, I had difficulties with my broker not participating and I was similarly impressed that arrangements were made to allow my participation based on the production of proof of entitlement etc. I was informed that I’d receive something this week, which i’m still waiting for. At least I’m not the only one. Very happy to hold
I commented earlier on the Restricted Offer procedures for direct applicants, which I thought were pretty clunky.

Having not heard how many shares I had been allocated under the Restricted Offer, I called LINK today to find out what was going on. It was very unsatisfactory experience for a host of reasons and they had no record of my application or whether I had been issued any shares. Frankly, they were very polite, but clueless.

I e-mailed the company direct to ask what the hell was going on. Very impressively, the company secretary (Salim Hamir) called me back almost immediately to give me a very full explanation of the position and to confirm my share allocation. I cannot think of many companies who would bother to do that.

The admin behind the TRLS IPO has clearly been sub par, which is a real shame, given that the IPO itself has been so successful. I think that EKF and the companies that it has spun out are best in class in the way that they deal with retail investors.There are going to be further spin-outs. I think that lessons will be learnt from this one. I am posting this as I believe that there are still some applicants in the dark. The company is on the case.

The Amati AIM VCT this afternoon released their monthly factsheet, and had this to say FYI:

"New investments were made in Trellus Health, an IPO spin out from Mount Sinai facilitated by EKF Diagnostics. Trellus is commercialising 20 years of research by the academic founders who created the GRITT programme to help irritable bowel disorder (IBD) patients increase their resilience to the social-mental and ultimately biological aspects of their disease. Evidence shows that IBD patients with greater resilience are better able to self-manage their symptoms and become a lower burden on the healthcare system. Trellus is developing an AI powered platform to on-board, assess and guide patients through the GRITT programme with the help of a small healthcare team as well as deploy the GRITT methodology into other chronic disease areas."

Trellus has a great team, including experienced leaders/founders with real passion, commitment, vision and a genuine mission to improve patients lives, which the following exemplifies -

Trellus Health Co-Founder, Dr. Marla Dubinsky MD, Receives Uniting to Care & Cure Award from CCF
Media Coverage | June 14, 2021
Trellus Health Co-Founder, Dr. Marla Dubinsky, MD, was recently honored with the 2021 Uniting to Care & Cure Award from the Crohn’s & Colitis Foundation (CCF).

The award recognizes healthcare providers who have shown exceptional dedication to the Inflammatory Bowel Disease (IBD) community of patients and caregivers, and for advancing the CCF mission to improve patient quality of life and find cures for IBD.

Full release -

Obviously IBD is a chronic condition, and we know that Trellus will also eventually abe offering personalised care for other complex/chronic conditions.

The following recent interview indicates that virtual chronic care management is accelerating, fuelled by the rapid adoption of telehealth -

The Clinic by Cleveland Clinic CEO points to telehealth's future
Frank McGillin talks about "on-demand" virtual care, virtual second opinions, chronic care management via telemedicine and telehealth personalization.
Bill Siwicki
June 14, 2021

Demand for "on-demand" telehealth services will grow, technology will normalize access to health experts via telemedicine, virtual chronic care management is growing and personalization will influence telehealth engagement.

Q: Do you believe demand for "on-demand" virtual care will grow? If so, why?

A: The horse is out of the barn for virtual care. COVID-19 eliminated many of the barriers to virtual care that existed before the pandemic, from provider reluctance to lack of infrastructure to hesitance from consumers.

Now, people are finding that they like the convenience of virtual care – especially when they can get it on demand. One physician-consumer survey found more than half of consumers plan to use telehealth more after the pandemic than they did beforehand, while 92% of physicians expect to continue providing virtual care.

Q: What is the outlook for virtual chronic care management?

A: Virtual chronic care management is accelerating. It's a trend fueled not only by the rapid adoption of telehealth, but also the creative use of remote patient monitoring technologies to monitor and manage individuals' health.

Full article -

With perhaps some relevance to the above post, a couple of slides from EKF's 2021 – 2024 Growth Strategy that in my opinion also has some relevance here -

2. Exploit newly expanded capabilities to meet the demand for
contract manufacturing services
Leverage relationship with private sector partner to support their diagnostics strategy
EKF currently makes kits for their COVID sample collection product in USA,
UK and Germany
Customer is the largest distribution business in the world
Leveraging distribution business to move into ‘home diagnostics’
EKF perfect partner due to manufacturing capabilities in US, Europe and UK
EKF also a key regulatory partner
Collaborating on new molecular enzyme product to be made in Elkhart
Reliant on EKF for all diagnostic advice
Increasing demand for kit manufacturing
Substantial revenue and EBITDA growth opportunity

3. Seek complementary earnings-enhancing acquisitions with
key strategic value to the core business
Three growth areas identified

CLIA lab for diagnostic tests
– Further area of partnership with global private sector partner
– Potential to link to Trellus, Renalytix and Verici
– Move into $4bn US diagnostic testing market which has forecast CAGR of 13% from 2021 to 2027

Molecular assay and platform
– Plug and play assays providing simplified workflows and cost-effective logistics
– In-house molecular assays and development of assays for major platform providers
– Potential Point Of Care (POC) molecular instrument

Expansion of kitting capabilities
– Contract manufacturing for existing diagnostics companies
– Adding to our existing capabilities in USA, UK and Germany

Food for thought (given EKF's connection with a very large private sector partner)-

Amazon attracting multiple companies to telehealth service
An Amazon exec said that the organization has had "quite a bit of interest from other companies in using this service," according to CNBC.
Kat Jercich
June 10, 2021

Amazon Care has signed several companies to its telehealth service, an executive said during a Wall Street Journal event on Wednesday, as the consumer giant continues with plans to roll out the service to all 50 states by this summer.

Speaking at the WSJ Tech Health event, Amazon VP Babak Parviz said that "we’ve had quite a bit of interest from other companies in using this service," according to CNBC.

"We are planning to expand the digital component of this in the next few months to every state in the U.S.," said Parviz. "We'll also make it available to other company employees, besides Amazon, to use this, should they choose to sign up and use the service.

"The plan is to expand the service nationwide," he said.


"Amazon Care is a healthcare service that is 'cyber physical' – it's hybrid. It's part digital, part physical," said Parviz.

"It’s quite different from anything we’ve had in the past," he added.

Full story -

Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older

Your Recent History

Delayed Upgrade Clock